Key facts
- It has raised $2.9M across 1 recorded rounds; the latest was Early Stage VC ($5.9M) in Oct 2024.
- Notable investors include Longevitytech.fund.
- Klothea Bio has filed 1 Form D with the SEC, most recently Oct 2024 ($1.0M sold to 1 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Klothea Bio
Funding rounds
1 roundsAbout Klothea Bio
Provider of mRNA-based therapeutic development intended for addressing age-related disease mechanisms. The company's platform focuses on a proprietary mRNA delivery system and nanocarrier technology, designed to increase endogenous production of a key longevity protein, enabling biopharmaceutical and clinical research markets to access interventions aimed at extending healthy lifespan and treating metabolic or degenerative conditions.
- Sector
- Healthcare
- HQ
- Miami, FL, United States
- Founded
- 2024
- Employees
- 4
- Website
- klothea.com/
- Ownership
- Privately Held (backing)
Klothea Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Klothea Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Klothea Bio in its N-PORT filings yet. We sweep new filings monthly.